安罗替尼治疗小细胞肺癌的临床应用与 研究进展
Clinical Application and Research Progress of Anlotinib in the Treatment of Small Cell Lung Cancer
DOI: 10.12677/acm.2026.1631090, PDF,   
作者: 张袁媛*：成都中医药大学医学与生命科学学院，四川 成都；陈耀华#：达州市中心医院呼吸与危重症医学科，四川 达州
关键词: 小细胞肺癌；安罗替尼；抗血管生成；临床疗效；联合治疗；Small Cell Lung Cancer； Anlotinib； Anti-Angiogenesis； Clinical Efficacy； Combination Therapy
摘要: 小细胞肺癌(small cell lung cancer, SCLC)是一种高度侵袭性的肺癌类型，常伴随较差的预后，亟需有效的治疗方案。近年来，安罗替尼(Anlotinib)作为一种新型抗血管生成药物在小细胞肺癌患者的治疗中受到了广泛关注。其通过抑制血管内皮生长因子受体、成纤维细胞生长因子受体等多个靶点抑制肿瘤细胞的增殖、促进细胞凋亡以及抗肿瘤血管生成等机制，可能改善患者的生存率和生活质量。然而，其在临床应用中仍面临耐药性及个体差异等挑战。当前研究显示，安罗替尼在小细胞肺癌患者中具有一定的临床疗效，但其具体作用机制尚需进一步阐明。联合治疗策略有望提升安罗替尼疗效并优化治疗方案。本文系统综述安罗替尼在小细胞肺癌患者治疗中的应用，探讨其在小细胞肺癌中临床潜力，以期为临床实践提供参考。
Abstract: Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, often with a poor prognosis, and thus requires effective treatment options. In recent years, anlotinib, as a novel anti-angiogenic drug, has received considerable attention in the treatment of patients with small cell lung cancer. It inhibits tumor cell proliferation, promotes cell apoptosis, and blocks tumor angiogenesis through multiple targets such as vascular endothelial growth factor receptors and fibroblast growth factor receptors, potentially improving the survival rate and quality of life of patients. However, it still faces challenges such as drug resistance and individual differences in clinical application. Current studies show that anlotinib has certain clinical efficacy in patients with small cell lung cancer, but its specific mechanism of action still needs to be further clarified. Combined treatment strategies are expected to enhance the efficacy of anlotinib and optimize the treatment plan. This article systematically reviews the application of anlotinib in the treatment of small cell lung cancer patients, explores its clinical potential and future research directions, with the aim of providing a reference for clinical practice.
文章引用：张袁媛, 陈耀华. 安罗替尼治疗小细胞肺癌的临床应用与 研究进展[J]. 临床医学进展, 2026, 16(3): 2878-2888. https://doi.org/10.12677/acm.2026.1631090

参考文献

[1] 刘通, 徐健, 许凝. CIK细胞免疫治疗联合化疗治疗广泛期SCLC一例[J]. 实用肿瘤杂志, 2021, 36(3): 218-221.
[2] Yuan, J., Cheng, F., Xiao, G., Wang, X. and Fan, H. (2022) Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study. Frontiers in Oncology, 12, Article 917089. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, Y., Jia, B., Li, J. and Xu, X. (2020) Anlotinib in Treatment of an Elderly Patient with Recurrent Advanced SCLC. Tumori Journal, 106, NP36-NP40. [Google Scholar] [CrossRef] [PubMed]
[4] Yang, S., Zhang, W., Chen, Q. and Guo, Q. (2020) Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study. Cancer Management and Research, 12, 10333-10340. [Google Scholar] [CrossRef] [PubMed]
[5] Wang, N., Zhao, L., Zhang, D. and Kong, F. (2022) Efficacy and Safety of Anlotinib as Maintenance Therapy after Induction Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Anti-Cancer Drugs, 34, 558-562. [Google Scholar] [CrossRef] [PubMed]
[6] Gao, T., Zhao, P., He, X., Zhao, M., Shang, Y. and Si, X. (2024) A Meta-Analysis Assessing the Therapeutic Efficacy and Safety of Anlotinib in Combination with Chemotherapy for Small Cell Lung Cancer. Pharmacology, 110, 231-253. [Google Scholar] [CrossRef] [PubMed]
[7] Du, Y., Liu, X., Si, X., Zhang, X., Zhou, J., Wang, Y., et al. (2024) Comparative Efficacy and Safety of Anlotinib and Topotecan as Second-Line Treatment in Small Cell Lung Cancer: A Retrospective Cohort Study. Translational Lung Cancer Research, 13, 1518-1529. [Google Scholar] [CrossRef] [PubMed]
[8] Muntean, C., Solomon, A., Cipaian, R.C., Vonica, R.C., Butuca, A., Gaborean, V., et al. (2025) The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review. Journal of Clinical Medicine, 14, Article 338. [Google Scholar] [CrossRef] [PubMed]
[9] Lv, B., Chen, J. and Liu, X. (2022) Anlotinib-Induced Hypertension: Current Concepts and Future Prospects. Current Pharmaceutical Design, 28, 216-224. [Google Scholar] [CrossRef] [PubMed]
[10] Xu, H., Liang, Y., Tang, W., Yang, X. and Du, X. (2024) Efficacy and Safety of Anlotinib Combined with S-1 as a Third-or Later-Line Treatment for Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis. Oncology Letters, 28, Article No. 613. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, G., Wang, Y., Jin, C. and Sun, X. (2025) Off-label Use of Anlotinib in Malignancies’ Treatment: Efficacy and Management of Adverse Reactions. Pharmacological Reports, 77, 392-408. [Google Scholar] [CrossRef] [PubMed]
[12] Li, T., Qian, Y., Zhang, C., Uchino, J., Provencio, M., Wang, Y., et al. (2021) Anlotinib Combined with Gefitinib Can Significantly Improve the Proliferation of Epidermal Growth Factor Receptor-Mutant Advanced Non-Small Cell Lung Cancer in Vitro and in Vivo. Translational Lung Cancer Research, 10, 1873-1888. [Google Scholar] [CrossRef] [PubMed]
[13] Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., et al. (2018) Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development. Journal of Hematology & Oncology, 11, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[14] Li, J., Zhang, D., Liu, Z., Wang, Y., Li, X., Wang, Z., et al. (2023) The Combined Effect and Mechanism of Antiangiogenic Drugs and PD-L1 Inhibitor on Cell Apoptosis in Triple Negative Breast Cancer. Annals of Translational Medicine, 11, 83-83. [Google Scholar] [CrossRef] [PubMed]
[15] Lin, B., Song, X., Yang, D., Bai, D.S., Yao, Y.Y. and Lu, N. (2020) Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1. Gene, 654, 77-86.
[16] Li, S. and Wang, H. (2023) Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib. Drug Design, Development and Therapy, 17, 3429-3437. [Google Scholar] [CrossRef] [PubMed]
[17] Li, J., Cao, P., Chen, Y., Wang, J., Sun, X., Chen, R., et al. (2022) Anlotinib Combined with the PD-L1 Blockade Exerts the Potent Anti-Tumor Immunity in Renal Cancer Treatment. Experimental Cell Research, 417, Article ID: 113197. [Google Scholar] [CrossRef] [PubMed]
[18] Zhao, X., Zhao, R., Wen, J., Zhang, X., Wu, S., Fang, J., et al. (2022) Anlotinib Reduces the Suppressive Capacity of Monocytic Myeloid-Derived Suppressor Cells and Potentiates the Immune Microenvironment Normalization Window in a Mouse Lung Cancer Model. Anti-Cancer Drugs, 34, 1018-1024. [Google Scholar] [CrossRef] [PubMed]
[19] Yang, Y., Li, L., Jiang, Z., Wang, B. and Pan, Z. (2020) Anlotinib Optimizes Anti-Tumor Innate Immunity to Potentiate the Therapeutic Effect of PD-1 Blockade in Lung Cancer. Cancer Immunology, Immunotherapy, 69, 2523-2532. [Google Scholar] [CrossRef] [PubMed]
[20] Hu, H., Liu, Y., Tan, S., Xie, X.X., He, J., Luo, F., et al. (2020) Anlotinib Exerts Anti-Cancer Effects on Kras-Mutated Lung Cancer Cell through Suppressing the MEK/ERK Pathway. Cancer Management and Research, 12, 3579-3587. [Google Scholar] [CrossRef] [PubMed]
[21] Tang, X., Zheng, Y., Jiao, D., Chen, J., Liu, X., Xiong, S., et al. (2021) Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of C-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells. Anti-Cancer Agents in Medicinal Chemistry, 21, 747-755. [Google Scholar] [CrossRef] [PubMed]
[22] Tang, H., You, T., Ge, H., Gao, J., Wang, Y., Bai, C., et al. (2024) Anlotinib May Enhance the Efficacy of Anti-Pd1 Therapy by Inhibiting the AKT Pathway and Promoting the Apoptosis of CAFs in Lung Adenocarcinoma. International Immunopharmacology, 133, Article ID: 112053. [Google Scholar] [CrossRef] [PubMed]
[23] Jiang, Z., Sun, X., Li, Y., Wang, J., Wang, C., Pan, Z., et al. (2025) Anlotinib Induced Ferroptosis through the P53/xCT/GPX4 Pathway in Non-Small Cell Lung Cancer. Translational Oncology, 53, Article ID: 102289. [Google Scholar] [CrossRef] [PubMed]
[24] Xia, X., Pi, W., Lan, Y., Wu, X., Lv, D., Meng, Y., et al. (2022) Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer. Analytical Cellular Pathology, 2022, Article ID: 4484211. [Google Scholar] [CrossRef] [PubMed]
[25] Han, D., Zhang, J., Bao, Y., Liu, L., Wang, P. and Qian, D. (2022) Anlotinib Enhances the Antitumor Immunity of Radiotherapy by Activating cGAS/STING in Non-Small Cell Lung Cancer. Cell Death Discovery, 8, Article No. 468. [Google Scholar] [CrossRef] [PubMed]
[26] Yuan, M., Zhai, Y., Men, Y., Zhao, M., Sun, X., Ma, Z., et al. (2022) Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐l1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 5479491. [Google Scholar] [CrossRef] [PubMed]
[27] Su, Y., Luo, B., Lu, Y., Wang, D., Yan, J., Zheng, J., et al. (2021) Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma. Clinical Cancer Research, 28, 793-809. [Google Scholar] [CrossRef] [PubMed]
[28] Jiang, H., Li, W., Zhang, B., Gong, Q. and Qie, H. (2021) Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study. International Journal of General Medicine, 14, 7625-7637. [Google Scholar] [CrossRef] [PubMed]
[29] Cheng, Y., Han, B., Li, K., et al. (2020) Effect of Anlotinib as A third-or Further-Line Therapy in Advanced Non-Small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial. Cancer Medicine, 9, 2621-2630.
[30] Cheng, Y., Wang, Q., Li, K., Shi, J., Liu, Y., Wu, L., et al. (2021) Anlotinib vs Placebo as Third-or Further-Line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study. British Journal of Cancer, 125, 366-371. [Google Scholar] [CrossRef] [PubMed]
[31] Yang, S., Zhang, Z. and Wang, Q. (2019) Emerging Therapies for Small Cell Lung Cancer. Journal of Hematology & Oncology, 12, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, Y., Cheng, Y., Li, K., Shi, J., Liu, Y., Wu, L., et al. (2021) Effect of Prior Thoracic Radiotherapy on Prognosis in Relapsed Small Cell Lung Cancer Patients Treated with Anlotinib: A Subgroup Analysis of the ALTER 1202 Trial. Translational Lung Cancer Research, 10, 3793-3806. [Google Scholar] [CrossRef] [PubMed]
[33] Shi, J., Cheng, Y., Wang, Q., Li, K., Wu, L., Han, B., et al. (2022) Anlotinib as Third-or Further-Line Therapy for Short-Term Relapsed Small-Cell Lung Cancer: Subgroup Analysis of a Randomized Phase 2 Study (ALTER1202). Frontiers of Medicine, 16, 766-772. [Google Scholar] [CrossRef] [PubMed]
[34] Cheng, Y., Wang, Q., Li, K., Shi, J., Wu, L., Han, B., et al. (2021) Anlotinib for Patients with Small Cell Lung Cancer and Baseline Liver Metastases: A Post Hoc Analysis of the ALTER 1202 Trial. Cancer Medicine, 11, 1081-1087. [Google Scholar] [CrossRef] [PubMed]
[35] Cheng, Y., Wang, Q., Li, K., Shi, J., Han, B., Wu, L., et al. (2023) Third‐line or above Anlotinib in Relapsed and Refractory Small Cell Lung Cancer Patients with Brain Metastases: A Post Hoc Analysis of ALTER1202, a Randomized, Double‐Blind Phase 2 Study. Cancer Innovation, 2, 181-190. [Google Scholar] [CrossRef] [PubMed]
[36] Chen, Q., Li, Y., Zhang, W., Wang, C., Yang, S. and Guo, Q. (2021) Safety and Efficacy of ICI Plus Anlotinib vs. Anlotinib Alone as Third-Line Treatment in Extensive-Stage Small Cell Lung Cancer: A Retrospective Study. Journal of Cancer Research and Clinical Oncology, 148, 401-408. [Google Scholar] [CrossRef] [PubMed]
[37] Kong, F., Wang, Z., Wang, N., et al. (2023) Maintenance Anlotinib Improves the Survival Prognosis of Extensive-Stage Small Cell Lung Cancer: A Single-Arm, Prospective, Phase II Study. American Journal of Cancer Research, 13, 3679-3685.
[38] Kong, T., Chen, L., Zhao, X., Duan, F., Zhou, H., Wang, L., et al. (2022) Anlotinib Plus Etoposide and Cisplatin/Carboplatin as First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Single-Arm, Phase II Study. Investigational New Drugs, 40, 1095-1105. [Google Scholar] [CrossRef] [PubMed]
[39] Zheng, H., Jiang, A., Gao, H., Liu, N., Zheng, X., Fu, X., et al. (2022) The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study. Cancer Management and Research, 14, 2273-2287. [Google Scholar] [CrossRef] [PubMed]
[40] Wu, Y., Zhou, X., Zhao, W., Wang, Q., Han, Z., Wang, L., et al. (2023) Therapeutic Effectiveness of Anlotinib Combined with Etoposide in Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Phase II Trial. Investigational New Drugs, 41, 825-833. [Google Scholar] [CrossRef] [PubMed]
[41] Peng, Y., Wu, D., Tang, J. and Li, X. (2025) Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients Who Have Achieved Stable-Disease after First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study. Cancer Control, 32. [Google Scholar] [CrossRef] [PubMed]
[42] Ma, J., Ma, X., Zhang, W., Hu, S., Zang, R., Wu, X., et al. (2025) Anlotinib as Maintenance Therapy after First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer. Technology in Cancer Research & Treatment, 24. [Google Scholar] [CrossRef] [PubMed]
[43] Zhang, J., Wu, Z., Wang, S., Sun, Y., Wu, J., Wang, D., et al. (2025) Efficacy of PD-(L)1 Inhibitors plus Anlotinib in the Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer. BMC Cancer, 25, Article No. 1070. [Google Scholar] [CrossRef] [PubMed]
[44] Ying, X., Shi, Z., Shao, R., You, G. and Song, Z. (2024) Correction: Efficacy and Safety Analysis of Anlotinib in Combination with Immune Checkpoint Inhibitors for Second-Line and Subsequent Extensive-Stage Small-Cell Lung Cancer. Neoplasma, 71, 509-509. [Google Scholar] [CrossRef] [PubMed]
[45] Gao, G., Sun, M., Yang, Z., Li, J., Ji, H. and Yu, G. (2025) Combining Immunotherapy with Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Analysis of Efficacy and Safety. Technology in Cancer Research & Treatment, 24. [Google Scholar] [CrossRef] [PubMed]
[46] Cheng, Y., Chen, J., Zhang, W., Xie, C., Hu, Q., Zhou, N., et al. (2024) Benmelstobart, Anlotinib and Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase 3 Trial. Nature Medicine, 30, 2967-2976. [Google Scholar] [CrossRef] [PubMed]
[47] Fatehi Hassanabad, A. and MacQueen, K.T. (2020) Molecular Mechanisms Underlining the Role of Metformin as a Therapeutic Agent in Lung Cancer. Cellular Oncology, 44, 1-18. [Google Scholar] [CrossRef] [PubMed]
[48] Storozhuk, Y., Hopmans, S.N., Sanli, T., Barron, C., Tsiani, E., Cutz, J., et al. (2013) Metformin Inhibits Growth and Enhances Radiation Response of Non-Small Cell Lung Cancer (NSCLC) through ATM and AMPK. British Journal of Cancer, 108, 2021-2032. [Google Scholar] [CrossRef] [PubMed]
[49] Luo, Z., Chen, W., Wu, W., Luo, W., Zhu, T., Guo, G., et al. (2019) Metformin Promotes Survivin Degradation through AMPK/PKA/GSK-3β-axis in Non-Small Cell Lung Cancer. Journal of Cellular Biochemistry, 120, 11890-11899. [Google Scholar] [CrossRef] [PubMed]
[50] Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., et al. (2009) Metformin Inhibits Breast Cancer Cell Growth, Colony Formation and Induces Cell Cycle Arrest in Vitro. Cell Cycle, 8, 909-915. [Google Scholar] [CrossRef] [PubMed]
[51] Dowling, R.J., Goodwin, P.J. and Stambolic, V. (2011) Understanding the Benefit of Metformin Use in Cancer Treatment. BMC Medicine, 9, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[52] Chen, Y. and Wang, X. (2024) Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer. British Journal of Hospital Medicine, 85, 1-14. [Google Scholar] [CrossRef] [PubMed]
[53] Zhu, Z., Jiang, T., Suo, H., Xu, S., Zhang, C., Ying, G., et al. (2021) Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and Ros-Mediated Signaling Pathways. Frontiers in Pharmacology, 12, Article 712181. [Google Scholar] [CrossRef] [PubMed]
[54] Xia, H., Tai, X., Cheng, W., Wu, Y., He, D., Wang, L., et al. (2025) Metformin Inhibits the Growth of SCLC Cells by Inducing Autophagy and Apoptosis via the Suppression of EGFR and AKT Signalling. Scientific Reports, 15, Article No. 6081. [Google Scholar] [CrossRef] [PubMed]
[55] Cao, X., Wen, Z., Wang, X., Li, Y., Liu, K. and Wang, X. (2017) The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-Analysis of Retrospective Studies. Journal of Cancer, 8, 2532-2541. [Google Scholar] [CrossRef] [PubMed]
[56] Han, B., Zhang, B., Zhong, R., Shi, C., Chu, T., Zhang, W., et al. (2024) MA17.07 Durvalumab Plus Anlotinib versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial. Journal of Thoracic Oncology, 19, S125-S126. [Google Scholar] [CrossRef] 
[57] Qu, X. (2026) A Single-Arm, Phase II Study of Sacituzumab Tirumotecan Combined with Anlotinib in Patients with Extensive-Stage Small Cell Lung Cancer after Failure of PD-(L)1 Inhibitor plus Chemotherapy (Registry No. NCT07388875) [Clinical Trial Registration]. ClinicalTrials.gov.
https://ichgcp.net/clinical-trials-registry/NCT07388875
[58] Lu, J., Xu, W., Qian, J., Wang, S., Zhang, B., Zhang, L., et al. (2019) Transcriptome Profiling Analysis Reveals That CXCL2 Is Involved in Anlotinib Resistance in Human Lung Cancer Cells. BMC Medical Genomics, 12, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[59] Zhang, L., Lu, J., Liu, R., Hu, M., Zhao, Y., Tan, S., et al. (2020) Chromatin Accessibility Analysis Reveals That TFAP2A Promotes Angiogenesis in Acquired Resistance to Anlotinib in Lung Cancer Cells. Acta Pharmacologica Sinica, 41, 1357-1365. [Google Scholar] [CrossRef] [PubMed]
[60] 正大天晴药业集团股份有限公司. 盐酸安罗替尼胶囊说明书[EB/OL]. 2022-04-08.
https://www.cttq.com/product/zhongliu-detail-25405.htm, 2023-03-13.
[61] Deng, P., Hu, C., Li, Y., et al. (2020) Bronchial Fistula: Rare Complication of Treatment with Anlotinib. Chinese Journal of Lung Cancer, 23, 858-865.
[62] Nan, D., Yin, X., Ma, D., Jiang, X., Wu, B. and Feng, J. (2021) Posterior Reversible Encephalopathy Syndrome Associated with Anlotinib: A Case Report and Literature Review. Frontiers in Neurology, 12, Article 546481. [Google Scholar] [CrossRef] [PubMed]
[63] Cohen, J.B., Brown, N.J., Brown, S., Dent, S., van Dorst, D.C.H., Herrmann, S.M., et al. (2023) Cancer Therapy-Related Hypertension: A Scientific Statement from the American Heart Association. Hypertension, 80, e46-e57. [Google Scholar] [CrossRef] [PubMed]
[64] Lu, J., Shi, Q., Zhang, L., Wu, J., Lou, Y., Qian, J., et al. (2019) Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. Frontiers in Oncology, 9, Article 886. [Google Scholar] [CrossRef] [PubMed]

为你推荐